Printer Friendly

TELIOS ANNOUNCES OCUNEX(TM) OPHTHALMIC SOLUTION DEVELOPMENTS

 SAN DIEGO, July 19 /PRNewswire/ -- Telios Pharmaceuticals Inc. (the "company") (NASDAQ: TLIO) announced today that it had received the results of an early Phase II clinical study of the use of OcuNex(TM) ophthalmic solution in the treatment of corneal wounds associated with severe dry eye conducted in Japan by its development partner, Ono Pharmaceutical Co. Ltd. In this study involving 55 evaluable patients, preliminary analysis showed a statistically significant reduction in Rose Bengal staining in eyes treated with OcuNex(TM) ophthalmic solution as compared to those receiving chondroitin sulfate as placebo. Rose Bengal staining is a clinically accepted means to evaluate the progress of dry eye and was one of the primary endpoints of the study.
 Ono, however, indicated that while these early Phase II results suggested certain efficacy of OcuNex(TM) ophthalmic solution, these results did not support additional development efforts in Japan, Korea, and Taiwan due, among other things, to the presence of low-priced competing products in Japan and the belief that it will be difficult to obtain an acceptable approved price from Japanese regulatory authorities.
 Telios soon will initiate a late Phase II clinical trial in the United States pursuant to an approved investigational new drug application to further study the efficacy of OcuNex(TM) ophthalmic solution. The results of this study are not expected until the second half of 1994.
 Ono has indicated an interest in receiving the results of Telios' upcoming study in order to reconsider its position in the event that strong efficacy is demonstrated. The company plans to re-evaluate its development plans for OcuNex(TM) ophthalmic solution following analysis of the results of this study.
 Ono continues as the owner of 2,166,667 shares (8.9 percent) of Telios common stock and is the development partner of Telios for decorin in Japan, Korea, and Taiwan. Decorin is a research stage product being developed to treat fibrotic diseases such as those afflicting the kidneys, lungs, and liver.
 Telios is developing a new class of therapeutic products based upon research into the role of the extracellular matrix. The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic diseases, cardiovascular diseases and osteoporosis.
 -0- 7/19/93
 /CONTACT: Audrey D. Keane, director of corporate development of Telios, 619-622-2615/
 (TLIO)


CO: Telios Pharmaceutical Inc.; Ono Phamaceutical Co. Ltd. ST: California IN: MTC SU: JVN

LM-BP -- SD006 -- 3302 07/19/93 18:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 19, 1993
Words:410
Previous Article:TEXAS EASTERN TRANSMISSION CORPORATION TO PROVIDE FIRM SERVICE TO FOUR NORTHEASTERN UTILITIES
Next Article:STERLING SAVINGS ASSOCIATION OF SPOKANE, WASH., ANNOUNCES ACQUISITION OF SIX KEY BANK OF WASHINGTON BRANCH PROPERTIES
Topics:


Related Articles
LEADING RESEARCHERS REPORT THAT TP-9201 PREVENTS BLOOD CLOTTING WITHOUT INCREASING BLEEDING TIME
TELIOS ANNOUNCES NORSK HYDRO DECISION
TELIOS COMMENCES ADVANCED PHASE II STUDY FOR OCUNEX OPHTHALMIC SOLUTION
TELIOS FILES IND FOR ANTI-THROMBOTIC PEPTIDE, TP-9201
TELIOS ANNOUNCES FIRST QUARTER 1994 RESULTS
FDA ACCEPTS FILING OF TELIOS' PMA FOR ARGIDENE(TM) GEL
TELIOS PHARMACEUTICALS ANNOUNCES PRELIMINARY RESULTS OF DIABETIC FOOT ULCER STUDY
PHASE I CLINICAL TRIAL AFFIRMS DISTINCTIVE SAFETY PROFILE OF TELIOS' PLATELET AGGREGATION INHIBITOR TP-9201
TELIOS PHARMACEUTICALS ANNOUNCES CLINICAL RESULTS AND FOCUS ON REORGANIZATION
Integra LifeSciences Announces Patent Issued to Treat Thrombosis

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters